Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
50 hedge funds and large institutions have $352M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 6 closing their positions.
441% more capital invested
Capital invested by funds: $65.1M → $352M (+$287M)
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
35% more funds holding
Funds holding: 37 → 50 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$28.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$26.9M |
| 3 |
RI
RTW Investments
New York
|
+$21.8M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.17M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.55M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$397K |
| 4 |
BCM
Bourgeon Capital Management
Darien,
Connecticut
|
-$190K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$135K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
51
Eventide Asset Management
Boston,
Massachusetts
| – | -$2.17M | -377,000 | Closed |
|
|
52
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$397K | -68,975 | Closed |
|
|
BCM
53
Bourgeon Capital Management
Darien,
Connecticut
| – | -$190K | -33,000 | Closed |
|
|
VF
54
Virtu Financial
New York
| – | -$114K | -19,861 | Closed |
|
|
ARTA
55
A.R.T. Advisors
New York
| – | -$101K | -17,650 | Closed |
|
56
Group One Trading
Chicago,
Illinois
| – | -$36.8K | -5,000 | Closed |
|
57
Bank of America
Charlotte,
North Carolina
| – | -$2.66K | -362 | -91% |
|
DRNA Hedge Fund Activity: Q4 2017 in Review
50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2017, worth a combined $352M — up 441% from $65.1M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new DRNA positions and 6 closed out — a net gain of 14 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $28.5M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $2.17M sold.
- 50 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2017, up from 37 in Q3 2017.
- Funds reported $352M of Dicerna Pharmaceuticals, Inc. stock for Q4 2017, up 441% quarter-over-quarter.
- 20 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2017 and 6 closed out, a net change of +14 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2017 was EcoR1 Capital, an estimated $28.5M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2017 was Eventide Asset Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2017.